title: A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.
abstract: Decision makers increasingly request evidence on the real-world cost effectiveness of a new treatment. There is, however, a lack of practical guidance on how to conduct an economic evaluation based on registry data and how this evidence can be used in actual decision making. This paper explains the required steps on how to perform a sound economic evaluation using examples from an economic evaluation conducted with real-world data from the Dutch Population based HAematological Registry for Observational Studies. There are three main issues related to using registry data: confounding by indication, missing data, and insufficient numbers of (comparable) patients. If encountered, it is crucial to accurately deal with these issues to maximize the internal validity and generalizability of the outcomes and their value to decision makers. Multivariate regression modeling, propensity score matching, and data synthesis are well-established methods to deal with confounding. Multiple imputation methods should be used in cases where data are missing at random. Furthermore, it is important to base the incremental cost-effectiveness ratio of a new treatment compared with its alternative on comparable groups of (matched) patients, even if matching results in a small analytical population. Unmatched real-world data provide insights into the costs and effects of a treatment in a real-world setting. Decision makers should realize that real-world evidence provides extremely valuable and relevant policy information, but needs to be assessed differently compared with evidence derived from a randomized clinical trial.
authors: Department of Health Policy and Management, institute for Medical Technology Assessment, Erasmus University, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
authors: Hedwig M
authors: HM
authors: Blommestein
authors: Margreet G
authors: MG
authors: Franken
authors: Carin A
authors: CA
authors: Uyl-de Groot
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003657:Decision Making; D017408:Guidelines as Topic; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D009426:Netherlands; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic / Q000191:economics; D012042:Registries; D013222:State Medicine / Q000191:economics*
chemical_list: D000970:Antineoplastic Agents
references: Ann Oncol. 2008 Mar;19(3):570-6
references: 18056649
references: Value Health. 2009 Nov-Dec;12(8):1053-61
references: 19744292
references: Circulation. 2008 Sep 16;118(12):1294-303
references: 18794402
references: JAMA. 2009 Aug 19;302(7):790-1
references: 19690313
references: Appl Health Econ Health Policy. 2015 Jun;13(3):303-9
references: 25288052
references: JAMA. 2010 Aug 25;304(8):897-8
references: 20736474
references: Am J Med. 2010 Dec;123(12 Suppl 1):e16-23
references: 21184862
references: Pharmacogenomics. 2011 Mar;12(3):411-21
references: 21449679
references: Eur J Cancer. 2011 Sep;47(14):2188-94
references: 21621408
references: Eur J Cancer. 2013 Jan;49(1):8-16
references: 22809557
references: J Clin Pharm Ther. 2013 Feb;38(1):41-7
references: 23126374
references: Value Health. 2013 Mar-Apr;16(2):231-50
references: 23538175
references: Pharmacoeconomics. 2013 Aug;31(8):703-18
references: 23657918
references: Value Health. 2014 Mar;17(2):143-56
references: 24636373
references: Value Health. 2014 Mar;17(2):245-53
references: 24636383
references: Eur J Haematol. 2014;92(5):398-406
references: 24400940
references: Eur Arch Otorhinolaryngol. 2014 Jun;271(6):1673-8
references: 23907370
references: Z Evid Fortbild Qual Gesundhwes. 2014;108(7):358-9, 355-7
references: 25444292
references: Z Evid Fortbild Qual Gesundhwes. 2014;108(7):383-9
references: 25444296
references: Eur J Cancer Care (Engl). 2015 May;24(3):321-32
references: 24372941
references: Pharmacoeconomics. 2008;26(2):131-48
references: 18198933
references: Health Policy. 2007 Jan;80(1):135-43
references: 16621124
references: J Clin Epidemiol. 2006 Aug;59(8):819-28
references: 16828675
references: J Clin Epidemiol. 2006 May;59(5):437-47
references: 16632131
references: Pharmacoeconomics. 2006;24(4):355-71
references: 16605282
references: Am J Epidemiol. 2006 Feb 1;163(3):262-70
references: 16371515
references: Acta Oncol. 2008;47(6):1029-36
references: 18607857